TBPH (STOCKS)
Theravance Biopharma, Inc.
$19.550000
+0.150000 (+0.77%)
Prev close: $19.400000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Rick E. Winningham
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $988.11M
- Employees
- 97
- P/E (TTM)
- 34.49
- P/B (TTM)
- 4.22
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $80.33M |
| Benefits Costs and Expenses | $5.39M |
| Costs And Expenses | $33.35M |
| Operating Expenses | $113.14M |
| Selling, General, and Administrative Expenses | $73.63M |
| Research and Development | $39.51M |
| Operating Income/Loss | -$32.81M |
| Income/Loss From Continuing Operations After Tax | $29.34M |
| Income/Loss From Continuing Operations Before Tax | $74.93M |
| Income Tax Expense/Benefit | $17.90M |
| Income Tax Expense/Benefit, Deferred | -$18.14M |
| Net Income/Loss | $29.34M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $29.34M |
| Net Income/Loss Available To Common Stockholders, Basic | $29.34M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.58 |
| Diluted Earnings Per Share | $0.57 |
| Basic Average Shares | 50,294,000 |
| Diluted Average Shares | 51,133,000 |
| Assets | $415.46M |
| Current Assets | $354.70M |
| Noncurrent Assets | $60.76M |
| Fixed Assets | $6.26M |
| Other Non-current Assets | $54.51M |
| Liabilities | $182.78M |
| Current Liabilities | $37.41M |
| Accounts Payable | $2.21M |
| Wages | $10.33M |
| Other Current Liabilities | $24.86M |
| Noncurrent Liabilities | $145.37M |
| Equity | $232.68M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $232.68M |
| Liabilities And Equity | $415.46M |
| Net Cash Flow From Operating Activities | $243.70M |
| Net Cash Flow From Operating Activities, Continuing | $243.70M |
| Net Cash Flow From Investing Activities | -$90.19M |
| Net Cash Flow From Investing Activities, Continuing | -$90.19M |
| Net Cash Flow From Financing Activities | -$2.12M |
| Net Cash Flow From Financing Activities, Continuing | -$2.12M |
| Net Cash Flow | $151.40M |
| Net Cash Flow, Continuing | $151.40M |
| Comprehensive Income/Loss | $29.37M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $29.37M |
| Other Comprehensive Income/Loss | $25.00K |